Leadership Overview
Zai Lab has 5 executives leading key functions including financial oversight, research operations, and medical strategy.
Focused on advancing innovative therapies for oncology and autoimmune conditions, Zai Lab prioritizes rigorous drug discovery and global clinical development to address significant unmet medical needs within the international pharmaceutical landscape.
Focused on advancing innovative therapies for oncology and autoimmune conditions, Zai Lab prioritizes rigorous drug discovery and global clinical development to address significant unmet medical needs within the international pharmaceutical landscape.
Leadership Roles at Zai Lab
Diana Liu - Deputy Chief Financial Officer
Diana Liu, the Deputy Chief Financial Officer at Zai Lab, manages capital allocation strategies and financial reporting frameworks. Overseeing the fiscal health of the organization, the Deputy Chief Financial Officer ensures compliance with international accounting standards while supporting the expansion of oncology drug pipelines. This role involves coordinating with the board to optimize resource distribution across diverse research initiatives. By analyzing market trends, Diana Liu directly influences the long-term investment strategy for the company. The Deputy Chief Financial Officer maintains rigorous oversight of budgetary controls to sustain growth in the competitive bio-pharmaceutical sector. Through precise financial modeling, the Deputy Chief Financial Officer secures the necessary funding to accelerate drug discovery programs. This leadership position requires constant collaboration with internal stakeholders to align fiscal objectives with the broader mission of delivering life-saving treatments to patients across global markets.
Kari Lee - Deputy Chief Financial Officer
Kari Lee, the Deputy Chief Financial Officer at Zai Lab, oversees treasury operations and risk management protocols. Focusing on the liquidity requirements of the drug discovery business, the Deputy Chief Financial Officer implements strategies to mitigate financial exposure during large-scale clinical development projects. This role involves managing investor relations and communicating the financial impact of research milestones to external stakeholders. By evaluating the economic viability of new drug candidates, Kari Lee supports the executive team in prioritizing high-potential therapeutic assets. The Deputy Chief Financial Officer maintains internal controls to ensure transparency and accuracy in all financial disclosures. Through diligent monitoring of market volatility, the Deputy Chief Financial Officer protects the company's capital base. This leadership role requires deep integration with the operational teams to ensure that financial planning remains responsive to the rapid pace of innovation within the bio-pharmaceutical industry.
Xiaoxi Wang - Deputy Chief Financial Officer
Xiaoxi Wang, the Deputy Chief Financial Officer at Zai Lab, leads tax planning and corporate financial strategy. Managing the complexities of cross-border financial operations, the Deputy Chief Financial Officer ensures that the company maintains a sustainable tax structure while expanding its footprint in international markets. This role involves collaborating with legal and compliance departments to navigate the regulatory environments surrounding pharmaceutical manufacturing. By optimizing the cost structure of the drug discovery process, Xiaoxi Wang improves the overall profitability of the organization. The Deputy Chief Financial Officer provides critical insights into the financial feasibility of strategic partnerships and licensing agreements. Through rigorous analysis of operational expenses, the Deputy Chief Financial Officer drives efficiency across all departments. This leadership position requires a focus on long-term value creation, ensuring that the company remains well-positioned to fund future breakthroughs in oncology and autoimmune disease treatments.
James Yan - Chief Operating Officer, Research & Development
James Yan, the Chief Operating Officer, Research & Development at Zai Lab, directs the operational infrastructure supporting drug discovery and clinical trial execution. Managing the complex workflows of the research division, the Chief Operating Officer, Research & Development optimizes laboratory efficiency and accelerates the transition of candidates from preclinical phases to human trials. This role requires close coordination with scientific teams to ensure adherence to strict regulatory timelines. By streamlining internal processes, James Yan enhances the speed of innovation within the oncology and autoimmune portfolios. The Chief Operating Officer, Research & Development monitors the performance of global research sites to maintain high standards of data integrity. Through strategic resource management, the Chief Operating Officer, Research & Development drives the development of novel therapeutics. This leadership function ensures that the research pipeline remains robust and capable of meeting the evolving demands of the global pharmaceutical market.
Harald Reinhart - Chief Medical Officer
Harald Reinhart, the Chief Medical Officer at Zai Lab, directs the clinical development strategy and medical affairs for the entire drug portfolio. Overseeing the design and implementation of clinical trials, the Chief Medical Officer ensures that all research activities meet the highest safety and efficacy standards required by global health authorities. This role involves leading interactions with regulatory bodies to facilitate the approval of new oncology and autoimmune therapies. By providing medical expertise to the research teams, Harald Reinhart guides the selection of promising drug candidates. The Chief Medical Officer monitors patient outcomes and safety data to inform ongoing development decisions. Through collaboration with external medical experts, the Chief Medical Officer enhances the scientific credibility of the company's therapeutic pipeline. This leadership function is essential for translating complex scientific discoveries into viable medical solutions that improve patient health outcomes on a global scale.
Explore Leadership Teams in Manufacturing
Santen Pharmaceutical Co., Ltd., is a Japanese pharmaceutical company, specializing in ophthalmology. With its ophthalmic products Santen holds the top share within the Japanese market and is one of the leading ophthalmic companies worldwide, with its products being sold in over 50 countries. The company was founded in 1890 by Kenkichi Taguchi, as Taguchi Santendo, and in 1925, Santendo Co., Ltd. was established.
Company Leadership TI
RN
FA
Unither Pharmaceuticals is a global contract development and manufacturing organization (CDMO) specializing in the production of single-dose liquid pharmaceuticals and sterile unit-dose formats for the pharmaceutical and consumer healthcare industries. The company is recognized as a world leader in blow-fill-seal technology, an advanced aseptic manufacturing process that forms, fills, and seals plastic containers in a continuous automated operation, ensuring high levels of sterility and product integrity. Unither's expertise encompasses the development and manufacturing of various liquid dosage forms including oral solutions, suspensions, nasal sprays, eye drops, and other sterile and non-sterile pharmaceutical products delivered in innovative single-dose formats. The company serves a diverse client base of pharmaceutical companies, biotechnology firms, and consumer health brands, providing comprehensive services from formulation development and clinical trial manufacturing to commercial-scale production and packaging. With manufacturing facilities strategically located across multiple continents including Europe and North America, Unither maintains strict quality standards and regulatory compliance with international pharmaceutical guidelines including FDA and EMA requirements. The company emphasizes innovation in drug delivery systems, patient convenience, and sustainability while helping clients bring their pharmaceutical products to market efficiently through its specialized manufacturing capabilities and technical expertise in unit-dose liquid formulations.
Company Leadership JK
HH
ML
GG
Cresco Labs is a multi-state, vertically integrated cannabis company that controls its cultivation, manufacturing, extraction, and packaging practices. Its facilities are powered by agronomists, manufacturing experts, and state-of-the-art agricultural equipment, all of which drive their commitment to quality, purity, and consistency. Cresco Labs packages, ships and distributes its products nationwide, including locations owned and operated by their team. Cresco Labs is headquartered in Chicago, Illinois.
Company Leadership CR
GB
DD
Founded in 1974, New England BioLabs is a privately held company that produces and supplies recombinant and native enzyme reagents for the life science research, as well as providing solutions supporting genome editing, synthetic biology, and next-generation sequencing. NEB also provides free access to research tools such as REBASE, InBASE, and Polbase. The company is headquartered in Ipswitch, Massachusetts.
Company Leadership SR
LB
Frequently Asked Questions Regarding Zai Lab Top Executives and Leadership Team
